Molecular typing of colorectal cancer: Applications in diagnosis and treatment

Diagnostic Histopathology

Volumn 18, Issue 2, 2012, Pages 70-80

  Ibrahim, Ashraf E K ^a   Arends, Mark J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

BRAF; Cancer; Colorectal; KRAS; Lynch; Microsatellite instability

Indexed keywords

CETUXIMAB; K RAS PROTEIN; MICROSATELLITE DNA; PANITUMUMAB; RAS PROTEIN;

ARTICLE; CELL GROWTH; CELL SURVIVAL; COLON CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CANCER; DNA METHYLATION; DNA MICROARRAY; FAMILIAL CANCER; GENE EXPRESSION; GENE MUTATION; GENE SWITCHING; GENETIC ANALYSIS; GENOME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOLECULAR TYPING; NONHUMAN; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 84856226838     PISSN: 17562317     EISSN: 18767621     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2011.11.002     Document Type: Article

References (64)

1. Arends M.J., Frayling I. The genetics of colorectal cancer: mismatch repair deficiency in hereditary and sporadic colorectal cancer. Key advances in the effective management of colorectal cancer 2004, 25-40. Aesculapius Medical Press, London. D.T.C. Cunningham, A. Miles (Eds.).
2. Poulogiannis G., Ichimura K., Hamoudi R.A., et al. Prognostic relevance of DNA copy number changes in colorectal cancer. JPathol 2010, 220:338-347.
3. Poulogiannis G., McIntyre R., Dimitriadi M., et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A 2010, 107:15145-15150.
4. Frayling IM, Arends MJ. Adenomatous polyposis coli. In: Stanley Maloy, Kelly Hughes, eds. Brenners Encyclopedia of Genetics. 2nd edn. Edinburgh & London, UK: Elsevier, in press; Ch 16.
5. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
6. Sjoblom T., Jones S., Wood L.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
7. Naguib A., Wilson C.H., Adams D.J., Arends M.J. Activation of K-RAS by co-mutation of codons 19 and 20 is transforming. JMol Signal 2011, 6:2.
8. Barbacid M. ras genes. Annu Rev Biochem 1987, 56:779-827.
9. Katz M.E., McCormick F. Signal transduction from multiple Ras effectors. Curr Opin Genet Dev 1997, 7:75-79.
10. Shivapurkar N., Huang L., Ruggeri B., et al. K-ras and p53 mutations in aberrant crypt foci and colonic tumors from colon cancer patients. Cancer Lett 1997, 115:39-46.
11. Otori K., Oda Y., Sugiyama K., et al. High frequency of K-ras mutations in human colorectal hyperplastic polyps. Gut 1997, 40:660-663.
12. Andreyev H.J., Norman A.R., Cunningham D., et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001, 85:692-696.
13. Luo F., Brooks D.G., Ye H., et al. Conditional expression of mutated K-ras accelerates intestinal tumourigenesis in Msh2-deficient mice. Oncogene 2007, 26:4415-4427.
14. Min mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. Int J Exp Pathol 2009, 90:558-574.
15. Luo F., Ye H., Hamoudi R., et al. K-ras exon 4A has a tumour suppressor effect on carcinogen-induced murine colonic adenoma formation. JPathol 2010, 220:542-550.
16. Luo F., Poulogiannis G., Ye H., Hamoudi R., Arends M.J. Synergism between K-ras Val12 and mutant Apc accelerates murine large intestinal tumourigenesis. Oncol Rep 2011, 26:125-133.
17. Luo F., Poulogiannis G., Ye H., et al. Mutant K-ras promotes carcinogen-induced murine colorectal tumourigenesis, but does not alter tumour chromosome stability. JPathol 2011, 223:390-399.
18. Little A.S., Balmanno K., Sale M.J., et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal 2011, 4. ra17.
19. Plowman S.J., Arends M.J., Brownstein D.G., et al. The K-Ras 4A isoforms promotes apoptosis but does not affect either lifespan or spontaneous tumour incidence in ageing mice. Experimental Cell Research 2006, 312:16-26.
20. Castagnola P., Giaretti W. Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta 2005, 1756:115-125.
21. Sullivan K.M., Kozuch P.S. Impact of KRAS mutations on management of colorectal carcinoma. Patholog Res Int 2011, 2011. 219309.
22. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. JClin Oncol 2008, 26:1626-1634.
23. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. NEngl J Med 2008, 359:1757-1765.
24. van Krieken J.H., Jung A., Kirchner T., et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008, 453:417-431.
25. COSMIC Database SI Distribution of somatic mutations in KRAS 2011.
26. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
27. Allegra C.J., Jessup J.M., Somerfield M.R., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. JClin Oncol 2009, 27:2091-2096.
28. Naguib A., Cooke J.C., Happerfield L., et al. Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors. BMC Cancer 2011, 11:123.
29. Lin J.S., Webber E.M., Senger C.A., et al. Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. Am J Cancer Res 2011, 1:650-662.
30. Krens L.L., Baas J.M., Gelderblom H., Guchelaar H.J. Therapeutic modulation of K-ras signaling in colorectal cancer. Drug Discov Today 2010, 15:502-516.
31. Ma E.S., Wong C.L., Law F.B., et al. Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. JClin Pathol 2009, 62:886-891.
32. Toft N.J., Winton D.J., Kelly J., et al. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc Natl Acad Sci U S A 1999, 96:3911-3915.
33. Toft N.J., Curtis L.J., Sansom O.J., et al. Heterozygosity for p53 promotes microsatellite instability and tumorigenesis on a Msh2 deficient background. Oncogene 2002, 21:6299-6306.
34. Vasen H.F., Moslein G., Alonso A., et al. Guidelines for the clinical management of Lynch Syndrome (hereditary non-polyposis cancer). JMed Genet 2007, 44:353-362.
35. Thibodeau S.N., Bren G., Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993, 260:816-819.
36. Frayling I.M., Happerfield L., Mattocks C., Oakhill K., Arends M.J. Application of molecular diagnostics to hereditary nonpolyposis colorectal cancer. Molecular diagnostics, for the clinical laboratorian 2005, 375-392. Humana Press Inc, NJ. 2nd edn. W.B. Coleman, G.J. Tsongalis (Eds.).
37. Halford S., Sasieni P., Rowan A., et al. Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. Cancer Res 2002, 62:53-57.
38. Hawkins N.J., Ward R.L. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. JNatl Cancer Inst 2001, 93:1307-1313.
39. Jass J.R., Iino H., Ruszkiewicz A., et al. Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. Gut 2000, 47:43-49.
40. Jass J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007, 50:113-130.
41. Suter C.M., Martin D.I., Ward R.L. Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet 2004, 36:497-501.
42. Boland C.R. Clinical uses of microsatellite instability testing in colorectal cancer: an ongoing challenge. JClin Oncol 2007, 25:754-756.
43. Umar A., Boland C.R., Terdiman J.P., et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch Syndrome) and microsatellite instability. JNatl Cancer Inst 2004, 96:261-268.
44. Arends M.J., Ibrahim M., Happerfield L., Frayling I., Miller K. Interpretation of immunohistochemical analysis of mismatch repair (MMR) protein expression in tissue sections for investigation of suspected Lynch/Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome. UK NEQAS ICC & ISH Recommendations 2008, 1.
45. Arends M.J., Frayling I., Happerfield L., Ibrahim M. HNPCC/Lynch Syndrome Module: report of the immunohistochemical analysis of mismatch repair (MMR) protein expression. UK NEQAS ICC & ISH Recommendations 2010, 8.
46. Domingo E., Laiho P., Ollikainen M., et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. JMed Genet 2004, 41:664-668.
47. Benatti P., Gafa R., Barana D., et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005, 11:8332-8340.
48. Samowitz W.S., Curtin K., Ma K.N., et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001, 10:917-923.
49. Steinbakk A., Malpica A., Slewa A., et al. High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO Stage 1 cases. Anal Cell Pathol 2010, 33:245-255.
50. Gryfe R., Kim H., Hsieh E.T., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. NEngl J Med 2000, 342:69-77.
51. Carethers J.M., Chauhan D.P., Fink D., et al. Mismatch repair proficiency and invitro response to 5-fluorouracil. Gastroenterology 1999, 117:123-131.
52. Arnold C.N., Goel A., Boland C.R. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003, 106:66-73.
53. Meyers M., Wagner M.W., Mazurek A., Schmutte C., Fishel R., Boothman D.A. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. JBiol Chem 2005, 280:5516-5526.
54. Hemminki A., Mecklin J.P., Jarvinen H., Aaltonen L.A., Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000, 119:921-928.
55. Poulogiannis G., Frayling I.M., Arends M.J. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology 2010, 56:167-179.
56. Popat S., Hubner R., Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. JClin Oncol 2005, 23:609-618.
57. Cui H., Cruz-Correa M., Giardiello F.M., et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003, 299:1753-1755.
58. Ahuja N., Li Q., Mohan A.L., Baylin S.B., Issa J.P. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998, 58:5489-5494.
59. Meyer F., White E. Alcohol and nutrients in relation to colon cancer in middle-aged adults. Am J Epidemiol 1993, 138:225-236.
60. Gay L., Arends M.J., Mitrou P.N., et al. MLH1 promoter methylation, diet and lifestyle factors in mismatch repair deficient colorectal cancer patients from EPIC-Norfolk. Nutrition and Cancer 2011, 63:1000-1010.
61. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999, 96:8681-8686.
62. Weisenberger D.J., Siegmund K.D., Campan M., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006, 38:787-793.
63. Iacopetta B., Kawakami K., Watanabe T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?. Int J Clin Oncol 2008, 13:498-503.
64. Goel A., Nagasaka T., Arnold C.N., et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 2007, 132:127-138.